1. Home
  2. BTAI vs SGMA Comparison

BTAI vs SGMA Comparison

Compare BTAI & SGMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTAI
  • SGMA
  • Stock Information
  • Founded
  • BTAI 2017
  • SGMA 1993
  • Country
  • BTAI United States
  • SGMA United States
  • Employees
  • BTAI N/A
  • SGMA N/A
  • Industry
  • BTAI Biotechnology: Pharmaceutical Preparations
  • SGMA Electrical Products
  • Sector
  • BTAI Health Care
  • SGMA Technology
  • Exchange
  • BTAI Nasdaq
  • SGMA Nasdaq
  • Market Cap
  • BTAI 18.1M
  • SGMA 16.3M
  • IPO Year
  • BTAI 2018
  • SGMA 1994
  • Fundamental
  • Price
  • BTAI $0.34
  • SGMA $1.71
  • Analyst Decision
  • BTAI Buy
  • SGMA
  • Analyst Count
  • BTAI 4
  • SGMA 0
  • Target Price
  • BTAI $2.81
  • SGMA N/A
  • AVG Volume (30 Days)
  • BTAI 1.3M
  • SGMA 49.9K
  • Earning Date
  • BTAI 03-11-2025
  • SGMA 03-07-2025
  • Dividend Yield
  • BTAI N/A
  • SGMA N/A
  • EPS Growth
  • BTAI N/A
  • SGMA N/A
  • EPS
  • BTAI N/A
  • SGMA N/A
  • Revenue
  • BTAI $2,276,000.00
  • SGMA $336,558,119.00
  • Revenue This Year
  • BTAI $131.23
  • SGMA N/A
  • Revenue Next Year
  • BTAI $45.79
  • SGMA N/A
  • P/E Ratio
  • BTAI N/A
  • SGMA N/A
  • Revenue Growth
  • BTAI 83.25
  • SGMA N/A
  • 52 Week Low
  • BTAI $0.30
  • SGMA $1.50
  • 52 Week High
  • BTAI $4.17
  • SGMA $6.47
  • Technical
  • Relative Strength Index (RSI)
  • BTAI 42.14
  • SGMA 39.42
  • Support Level
  • BTAI $0.33
  • SGMA $1.62
  • Resistance Level
  • BTAI $0.39
  • SGMA $1.90
  • Average True Range (ATR)
  • BTAI 0.06
  • SGMA 0.13
  • MACD
  • BTAI -0.00
  • SGMA 0.03
  • Stochastic Oscillator
  • BTAI 9.27
  • SGMA 28.21

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About SGMA SigmaTron International Inc.

Sigmatron International Inc is an independent provider of electronic manufacturing services (EMS). It provides manufacturing and assembly services ranging from the assembly of individual components to the assembly and testing of box-build electronic products. The company manufactures products like printed circuit board assemblies, electro-mechanical subassemblies, and completely assembled (box-build) electronic products which are incorporated into finished products and sold in various industries, particularly industrial electronics, consumer electronics, and life sciences. In some instances, it manufactures and assembles the completed finished product for its customers. Geographically, the company derives maximum revenue from Mexico and the rest from the United States, China, and Vietnam.

Share on Social Networks: